Defunct Company
Total Trials
6
As Lead Sponsor
As Collaborator
0
Total Enrollment
584
NCT02904226
JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors
Phase: Phase 1/2
Role: Lead Sponsor
Start: Aug 31, 2016
Completion: Jul 1, 2020
NCT03790488
Study of a PD-1 Inhibitor (JTX-4014) in Subjects With Solid Tumor Malignancies
Phase: Phase 1
Start: Dec 6, 2018
Completion: Feb 28, 2023
NCT03989362
Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer
Phase: Phase 2
Start: Jun 6, 2019
Completion: Mar 15, 2022
NCT04319224
Vopratelimab (JTX-2011) Alone and in Combination With Anti-Programmed Cell Death Protein 1 (PD-1) or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) in Subjects With Advanced and/or Refractory Solid Tumors
Start: Mar 10, 2020
Completion: Jan 3, 2023
NCT04549025
Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab in Biomarker-selected Subjects With Metastatic NSCLC After One Prior Platinum-containing Regimen
Start: Oct 19, 2020
Completion: Apr 25, 2024
NCT04669899
Study of JTX-8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors
Start: Jan 12, 2021
Completion: Nov 28, 2023